A5042934235- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Blood groups and transfusion
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- HER2/EGFR in Cancer Research
- Hemoglobinopathies and Related Disorders
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- Blood properties and coagulation
- Nerve injury and regeneration
- Autism Spectrum Disorder Research
- CNS Lymphoma Diagnosis and Treatment
- Kruppel-like factors research
- Retinoids in leukemia and cellular processes
- Autoimmune and Inflammatory Disorders Research
- Lysosomal Storage Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Peripheral Neuropathies and Disorders
Hospital Universitario de Canarias
2013-2024
Universidad de La Laguna
2017-2024
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
University Clinical Hospital In Bialystok
2019
Hamilton Utilities Corporation
2019
Hudson Institute
2017
John Wiley & Sons (United States)
2017
Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated clinical trials good efficacy and safety profile after failure 2GTKI. However, no study specifically addressed response rates to asciminib ponatinib pretreated (PPT). Here, we present data on responses from 52 practice, 20 them (38%) prior exposure. We analyzed...
Management of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results daratumumab in heavily pre-treated patients. In this retrospective multicentric study, 38 (mean age 64 ± 9 years) R/R treated were included. Cardiac and renal involvement was present 76 74% patients, 42% had ≥3 organs involved. Median number previous lines therapy 2 (range 1–8). Overall hematological response 72%, including 28% complete responses. The median...
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction asciminib may be promising option intolerant patients, as it is first-in-class inhibitor more selective mechanism action different from ATP-competitive inhibition that occurs Therefore, our goal was to analyze toxicities shown well study cross-toxicity previous (2) Methods: An observational,...
To describe the reasons for and result of thrombopoietin receptor agonists (TPO-RA) switching in adult immune thrombocytopenia (ITP) patients 4 Spanish centres.We retrospectively analysed all who received sequential treatment with both TPO-RA between 2010 2015 recording clinical biological parameters.Twenty-six were included; 17 first romiplostim 9 eltrombopag. Reasons inefficacy (n = 10), patient preference 8), side effects 5) excessive platelet count fluctuation 3). When switch was due to...
Abstract Avatrombopag is the newest thrombopoietin receptor agonist (TPO‐RA) approved to treat immune thrombocytopenia (ITP). Real‐world evidence regarding effectiveness/safety limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for first time. A total of 268 were recruited. median (interquartile range [IQR]) follow‐up time was 47.5 (30.4–58.9) weeks. Among 193 baseline platelet counts <50 × 10 9 /L, 174 (90.1%) them achieved response...
Vancomycin-resistant enterococci (VRE) infections and outbreaks are still infrequent in Spain. A six-month outbreak, which took place a haematology ward, its control management described this study. total of 22 patients were colonised two bloodstream occurred during period. Even though there waves new patients, multidisciplinary approach, quick interventions enhanced infection policies required order to outbreak.
Immunoparesis (IP) in multiple myeloma (MM) patients can be measured by classic assessment of immunoglobulin (Ig) levels or analysis the uninvolved heavy/light chain pair same (uHLC) Hevylite® assay. In this study we evaluate prognostic value recovery from IP total Ig and uHLC newly diagnosed MM transplant-eligible (NDMM-TE) with intensive treatment its association Minimal Residual Disease (MRD). Patients were enrolled treated PETHEMA/GEM2012MENOS65 trial continued PETHEMA/GEM2014MAIN trial....
Sir, Compartment Syndrome is a life-threatening condition in which rapidly increasing interstitial pressures limb compartment compromise the vascular supply to tissues, causing ischaemic tissue injury. If uncorrected, necrosis may ensue, requiring amputation.[12] For prevention of intraoperative syndrome, importance an excellent intravenous access and constant visual monitoring catheter site often stressed.[3] We report unique case patient undergoing coronary artery bypass surgery (CABG)...
Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D 74 adult patients between 1990 2018. We found that 73% of showed response; almost all them had complete responses (68.9%), 26% achieved sustained at least 6 months after discontinuation. [Correction added on 02 December 2022, first online...
Background: Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first second line. However, vascular adverse events (VAEs) have been reported for patients with CML treated some TKIs. Methods: We retrospectively evaluated cumulative incidence (CI) cardiovascular risk 210 included Canarian Registry of CML. Result: With a mean follow up 6 years, 19/210 (9.1%) developed VAEs, all whom presented at least...
<title>Abstract</title> We conducted an observational and retrospective study to determine whether fatigue could predict thrombocytopenic episodes in ITP improvement platelet response. Data were collected from clinical records a survey. included 82 patients with who had at least one relapse. Fatigue was present 45 (54.9%), of whom 19 (23.2%) reported that preceded the episode (median 15 days prior) 18 (21.9%) resolved prior response confirmation 4 prior). In conclusion, may relapse or...
Patient-reported outcome measures (PROMs) and patient-reported experiences (PREMs) are crucial for understanding the impact of GD on quality life patient's perceptions care, but also to guide decision-making processes. Nevertheless, no specific PREMs in have been published, neither PROMs Spanish patients developed. Two project coordinators selected key-points be included a PROMs/PREMs questionnaire, scientific committee group expert contributed initial draft. Then, 9 meetings with experts...
<title>Abstract</title> Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated some observational and retrospective studies. We have evaluated impact IP its association with minimal residual disease (MRD) a series 113 newly diagnosed transplant-ineligible (NDTI) patients, that received fix duration treatment (18 cycles VMP/lenalidomide-dexamethasone) within PETHEMA/GEM2010MAS65 trial who achieved CR or VGPR. Immunoglobulin...